Neurocrine Biosciences
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 2 weeks.
- Recent price momentum is +3.4% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation B-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 22.3x | Better than 36% |
| Forward P/E | 17.0x | Better than 48% |
| Price / Sales | 4.5x | Better than 26% |
| P/E vs own 5-yr range | 12th pctl | Better than 90% |
Growth A
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 24.3% | Better than 86% |
| Net income CAGR (3Y) | 45.8% | Better than 87% |
| Free cash flow CAGR (3Y) | 32.4% | Better than 76% |
Profitability A
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 98.2% | Better than 99% |
| Operating margin | 22.3% | Better than 80% |
| Net margin | 16.7% | Better than 74% |
| Return on equity | 16.4% | Better than 71% |
| Return on invested capital | 12.4% | Better than 77% |
Momentum B-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -1.3% | Better than 70% |
| 6-month return | -3.9% | Better than 49% |
| 12-month return (ex latest month) | 1.0% | Better than 34% |
| Distance below 52-week high | 19.1% | Better than 62% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 3.4x | Better than 77% |
| Debt to assets | 9.0% | Better than 72% |
| Interest coverage | 4.8x | Better than 56% |
| Free cash flow / net income | 156.4% | Better than 67% |
Analyst View B+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 85.0% | Better than 67% |
| Upside to average target | 37.8% | Better than 57% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 156.59
- Open
- 156.27
- Day range
- 150.24 - 158.26
- Avg price
- 152.61
- Volume
- 1.59M
- Turnover
- 242.24M
- Turnover ratei
- 1.59%
- Volume ratioi
- 1.10
- Amplitudei
- 5.12%
- 52-week rangei
- 122.14 - 186.12
Valuation
- P/Ei
- 32.24
- P/E (TTM)i
- 22.34
- P/Bi
- 3.93
- EPSi
- 4.67
- Book value / shi
- 38.32
- Net profit
- 472.69M
- Net assets
- 3.88B
Share structure
- Market cap
- 15.24B
- Float capi
- 15.04B
- Shares out
- 101.22M
- Float sharesi
- 99.91M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
19.1% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-52.74M net over the window
Short interest
- Shares short
- 5.90M
- % of floati
- 5.81%
- Days to coveri
- 5.40
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Neurocrine Biosciences (NBIX)?
Neurocrine Biosciences last traded at 150.57. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Neurocrine Biosciences's market cap?
About 15.24B.
What is the P/E ratio of Neurocrine Biosciences?
The trailing twelve-month P/E is 22.34, below its own 5-year average of 98.52 — toward the bottom of its historical range (7.65% percentile). See the Valuation tab for the full history.
Does Neurocrine Biosciences pay a dividend?
Neurocrine Biosciences does not currently pay a regular dividend.
Is Neurocrine Biosciences a buy according to analysts?
The consensus of 19 analysts is a Buy rating, with an average 12-month price target of 207.35, which implies 37.7% upside from the current price. This is not investment advice.
What is Neurocrine Biosciences's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Neurocrine Biosciences a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.
Neurocrine Biosciences discussion 0 comments